in vitro News and Research

RSS

USPTO grants HemoShear patent for human cell-based surrogate systems

HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."

13 Oct 2010

NHC enter agreement with Attain to offer new program for IVF fertility treatments

IntegraMed America, Inc. the leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, today announced that its Attain Fertility Centers division has entered into an agreement with The New Hope Center for Reproductive Medicine (NHC) to begin offering the Attain IVF family of specialty financing Programs.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Incept completes first U.S. human clinical trial of SMART Start Embryo Culture System

Incept BioSystems, Inc. a privately-held biomedical device company using patented, microfluidic technology developed at the University of Michigan, announced today the completion of the first U.S. human clinical trial of its proprietary, SMART Start Embryo Culture System, and the recent submission of a 510(k) application to the U.S. Food & Drug Administration.

13 Oct 2010

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.

11 Oct 2010

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

11 Oct 2010

Paper describes new method for studying bacterial infection of orthopedic implants

A research team, co-headed by Dr. Woo Lee and Dr. Hongjun Wang of Stevens Institute of Technology, has published a paper describing a new method that generates three-dimensional tissue models for studying bacterial infection of orthopedic implants. Dr. Joung-Hyun Lee of Stevens, and Dr. Jeffrey Kaplan of the New Jersey Dental School, are co-authors of the research.

7 Oct 2010

IVF pioneer wins Nobel prize three decades after groundbreaking work

Yesterday's announcement that a pioneer of in vitro fertilization (IVF) for humans has won the Nobel prize for medicine three decades after his groundbreaking work adds new historical perspective to advancements in reproductive medicine, a sharp reminder of how a once-feared technology has transformed into a highly popular and routine treatment for infertility, said one of Southern California's earliest fertility doctors.

6 Oct 2010

Anticancer drug Cisplatin induces side effects

Cisplatin, an anticancer drug widely used for treating various types of tumor, can induce side effects in the short term. A team of scientists, mostly from CNRS and the Université de Nice has provided first in vitro evidence that this antitumor agent modifies the sensitivity of cellular pressure sensors. This completely novel mechanism could help to elucidate certain neurological side effects of cisplatin hitherto unexplained.

6 Oct 2010

Saneron receives grant to develop safety guidelines for transplanting HUBC cells in Alzheimer's disease

The National Institutes of Health has awarded a three-year, $2.6-million grant to the University of South Florida and Tampa-based biotechnology company Saneron-CCEL Therapeutics, Inc., to establish dosing and safety guidelines for transplanting human umbilical cord blood cells (HUBC) into animal models of Alzheimer's disease.

6 Oct 2010

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Cancer research is facing a radical change of direction. Cancer cells do not obtain their energy from the breakdown of sugar to carbon dioxide and water, but from energy-rich intermediates of sugar metabolism instead.

6 Oct 2010

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

Isogenica Ltd, today announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of NovaBiotic's platform peptide anti-infective technology.

6 Oct 2010

ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain

ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.

5 Oct 2010

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Enzon Pharmaceuticals, Inc. today announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company's novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.

5 Oct 2010

Department of Defense awards Banyan Biomarkers $26.3M contract to develop diagnostic test for TBI

Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.

5 Oct 2010

Combining computer simulations with laboratory experiments gives best results in drug development

While computer simulations of how the body metabolises drugs save both time and money,the best results when developing new drugs come from combining such simulations with laboratory experiments, reveals a researcher from the University of Gothenburg.

5 Oct 2010

cobas TaqScreen DPX Test now available with CE Mark: Roche

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay.

5 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

Father of IVF acknowledged with a Nobel prize

Professor Robert Edwards who came to be known as the “father of In Vitro fertilization” (IVF) has won this year's Nobel prize in medicine. He is 85 and has won the 2010 Nobel Prize in Physiology and Medicine for his pioneering work on the in vitro fertilisation of human eggs that led to the birth of the world's first IVF baby, Louise Brown, in 1978. When he had started off initially his funding request for IVF research was turned down by Britain’s Medical Research Council (MRC) in the 1970s. His co-worker the gynaecologist Patrick Steptoe, died in 1988. Professor Edwards becomes the sole recipient of this award since it cannot be awarded posthumously.

4 Oct 2010

Noninvasive embryo assessment technology may improve success rates for in vitro fertilization procedures

Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures.

4 Oct 2010

in vitro News and Research

USPTO grants HemoShear patent for human cell-based surrogate systems

NHC enter agreement with Attain to offer new program for IVF fertility treatments

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

Incept completes first U.S. human clinical trial of SMART Start Embryo Culture System

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Paper describes new method for studying bacterial infection of orthopedic implants

IVF pioneer wins Nobel prize three decades after groundbreaking work

Anticancer drug Cisplatin induces side effects

Saneron receives grant to develop safety guidelines for transplanting HUBC cells in Alzheimer's disease

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Department of Defense awards Banyan Biomarkers $26.3M contract to develop diagnostic test for TBI

Combining computer simulations with laboratory experiments gives best results in drug development

cobas TaqScreen DPX Test now available with CE Mark: Roche

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Father of IVF acknowledged with a Nobel prize

Noninvasive embryo assessment technology may improve success rates for in vitro fertilization procedures

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News